Skip Navigation LinksPress-Releases

Journal of Vascular Access Publishes Article by Eric D. Ladenheim, M.D.

This  article, entitled " First-week postoperative flow measurements are highly predictive of primary patency of radiocephalic arteriovenous fistulas" was recently published by The Journal of Vascular Access higlighting a study that was conducted to determine whether volume flow rate at the first postoperative visit could predict early failure of radiocephalic arteriovenous fistulas (RCAVFs).

You can read the full article here:

JVA-D-15-00174 First week flow.pdf

____________________________________________________________________________________________________________ 
New Mechanical Thrombectomy Device is used to Clean Out a Hemodialysis Graft:

Park City, Utah – Dr. Eric Ladenheim, a Surgeon at LDAC, Fresno, California, was successful in using a new device to remove thrombus from a hemodialysis graft. 

The patient presented with a two day old occluded dialysis graft.   A dialysis graft is a surgically placed tube or conduit that connects an artery to a vein for hemodialysis access.  A dialysis machine is used to clean the patient's blood, performing the normal function of the kidneys. 

Dr. Ladenheim first infused 2 mg of Tissue Plasminogen Activator ("TPA"), a thrombolytic agent, into the graft then gave 4000 units of heparin intravenously.   Dr. Ladenheim used the Aspire Mechanical Thrombectomy device to remove thrombus  in the graft.  Post thrombectomy, Dr. Ladenheim used an angioplasty balloon at the venous anastomosis then pulled the arterial plug with a thrombectomy balloon.

"The Aspire Mechanical Thrombectomy device shortened my procedure time and saved our facility significant cost, " said Dr. Ladenheim.  "A device that can save time and money is a value to my patients and me. "

The ASPIRE Mechanical Thrombectomy System allows clinicians to instantly start, stop, increase, decrease, pulse, or maintain thrombectomy force during a procedure.  ASPIRE Mechanical Aspirators also aspirate up to 280ml, almost 10 times more than basic syringe-based systems, without multiple messy and time-consuming catheter connections, disconnections, and re-connections to improve speed and performance.

"In todays healthcare environment, time and cost are important," said Chris Livingstone, vice president of sales for Control Medical Technology.  "The Aspire device is clinically effective, very simple to use and economically friendly to the healthcare systems."

The patented ASPIRE Mechanical Thrombectomy System is available by itself or in kits that include an over-the-wire or rapid exchange thrombectomy catheter.  ASPIRE Mechanical Aspirators may also be connected to any thrombectomy catheter the clinician chooses.

Control Medical Technology designs, develops, and markets innovative thrombus management, biopsy, and aspiration devices, including the patented ASPIRE Mechanical Aspirator™, ASPIRE RX-LP6 Mechanical Thrombectomy System™, and ASPIRE MAX Thrombectomy System™..  For more information, call 1-954-9345 or visit www.CONTROLMEDTECH.com.

aspire.png 

aspire2.png 

Control Medical Media contact: 

Chris Livingstone

(954) 534-9345

Chris@ASPIRATIONMEDICAL.com

 ____________________________________________________________________________________________________________

LDAC Physician presented Paper at the Vascular Society of the Americas meeting in Dallas, Texas on May 2nd, 2014:

Dr. Eric Ladenheim presented LDAC’s research showing how first week postoperative flow measurements are highly predictive of Primary Patency of Arteriovenous Fistulas. 

LDAC RESEARCH CITED BY MAJOR UNIVERSITY

Dr. Eric Ladenheim’s research cited in a study by Yale University, School of Medicine, Department of Vascular Surgery

New Haven, CT, August 13, 2013– Dr. Eric Ladenheim, President of LDAC Vascular Centers, has been cited in a study by Yale University, School of Medicine, Department of Vascular Surgery.

In an earlier study, conducted by Eric Ladenheim, MD, it was found that amputations healed significantly faster with a prefab plastic dressing placed immediately after surgery. His findings from his original study were confirmed in the study “A Comparison of Immediate Postoperative Rigid and Soft Dressings for Below-Knee Amputations” by B. Sumpio, S. R. Shine, D. Mahler, and B. E. Sumpio, from Yale University.

Background: A variety of postsurgical dressings are used after a below-knee amputation (BKA), but there is no evidence-based guideline on which dressing to use. The purpose of this study was to compare the application of immediate postoperative rigid dressings or soft dressings on the healing times of BKA.

Conclusions: Below-knee amputees had a significantly quicker healing time, as measured by the time to be cast for prosthesis, when a rigid dressing was used compared with a soft dressing. Consideration should be given to the use of a rigid dressing after BKA to expedite healing and promote earlier ambulation.

press-release.pdfyale-study.pdf

Press Release

In April 2012, Dr. Eric Ladenheim, President of Ladenheim Dialysis Access Centers, performed a study on the world’s leader of disposable tourniquets, HemaClear.

HemaClear is the original developer of sterile, disposable tourniquet technology that exsanguinates, occludes, and provides a clear surgical field. The technology not only reduces blood loss, infection, and the volume of ischemic tissue, its simplicity saves as much as 15 minutes of critical OR set-up time.

The study consisted of using sterile, disposable tourniquets on 27 patients performing forearm dialysis access surgery. The theory was to prevent blood loss in cases where upper arm procedures would have otherwise sustained substantial bleeding and need of blood transfusions. The conclusion was that there were no transfusions required and the HemaClear tourniquet proved more effective exsanguinations than pneumatic tourniquets.

The study was presented to the American Society of Diagnostic and Interventional Nephrology medical conference in New Orleans by Dr. Ladenheim on February 25, 2012 and won second prize.

The study occurred at Ladenheim Dialysis Access Center (LDAC) at 6057 N. First Street, Ste 105 Fresno, CA 93710. LDAC specializes in the surgical care of patients with chronic kidney disease and was organized in 2011.


On December 18, 2011, Central Valley Vascular Surgeon, Dr. Eric Ladenheim, performed the first human implant in the United States of an investigational device designed to help patients with Chronic Kidney Disease receive hemodialysis dialysis treatments.

The investigational device is known as the Venous Window Needle Guide. It is made by Vital Access, Inc. headquartered in Salt Lake City, Utah. It is currently being used as part of a clinical trial for patients receiving hemodialysis whose dialysis access is too deep to be readily used.

The surgery occurred at LDAC Surgery Center at 6153 N. Thesta Ave. Fresno, CA 93710. The LDAC Surgery Center specializes in the surgical care of patients with chronic kidney disease and was organized in 2011. The LDAC Surgery center is the latest addition to Dr. Ladenheim’s practice of dialysis access surgery and maintenance.

Venous Window Needle Guide

 

imagesURTOR1AK.jpg

steth.jpg 

imagesKC21NTCZ.jpg
imagesLK3EPOJI.jpg